The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m² intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia

Anne WanquetDépartement d’Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France;

Roberto CrocchioloDépartement d’Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France; ;Unité de Transplantation et de Thérapie Cellulaire (U2T), Institut Paoli-Calmettes, Marseille, France;

Sabine FurstDépartement d’Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France; ;Unité de Transplantation et de Thérapie Cellulaire (U2T), Institut Paoli-Calmettes, Marseille, France;

Angela GranataDépartement d’Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France; ;Unité de Transplantation et de Thérapie Cellulaire (U2T), Institut Paoli-Calmettes, Marseille, France;

Catherine FaucherDépartement d’Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France; ;Unité de Transplantation et de Thérapie Cellulaire (U2T), Institut Paoli-Calmettes, Marseille, France;

Raynier DevillierDépartement d’Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France; ;Unité de Transplantation et de Thérapie Cellulaire (U2T), Institut Paoli-Calmettes, Marseille, France;

Samia HarbiCentre de Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France

Claude LemarieCentre de Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France

Boris CalmelsDépartement d’Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France;

Norbert VeyDépartement d’Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France;

Pierre Jean WeillerCentre de Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France

Christian ChabannonDépartement d’Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France; ;Unité de Transplantation et de Thérapie Cellulaire (U2T), Institut Paoli-Calmettes, Marseille, France;

Luca CastagnaDépartement d’Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France; ;Unité de Transplantation et de Thérapie Cellulaire (U2T), Institut Paoli-Calmettes, Marseille, France;

Didier BlaiseDépartement d’Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France; ;Unité de Transplantation et de Thérapie Cellulaire (U2T), Institut Paoli-Calmettes, Marseille, France;

Jean El-CheikhDépartement d’Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France; ;Unité de Transplantation et de Thérapie Cellulaire (U2T), Institut Paoli-Calmettes, Marseille, France; Correspondence[email protected]

show all

The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m² intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m2 intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m² intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia